Source: Sharecast
Genedrive stated that following the UK's National Institute for Health and Care Excellence final published guidance that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke or Transient Ischaemic Attack, and that the Genedrive CYP2C19-ID test should be used as the test of choice for point of care strategies, an initial £100,000 order for its CYP2C19-ID Kit and instruments has been received to support an implementation assessment at Greater Manchester's Comprehensive Stroke Centre.
The AIM-listed group stated that after factoring in potential improvements in patient outcomes in addition to direct healthcare financial savings, implementation of CYP2C19 genotyping in IS/TIA has the potential value to the NHS of approximately £91.0m and £454.0m over one and five years, respectively.
Chief executive Dr Gino Miele said: "With recent NICE guidance recommending CYP2C19 genotyping strategies in the UK NHS for IS and TIA patients in the NHS who are eligible for receiving the antiplatelet Clopidogrel, and recommending our test as the point-of-care platform of choice, these initial first-sales of our CYP2C19 ID-kit in the UK to one of the largest stroke centres nationally is a key initial milestone in our CYP2C19 commercialisation strategy, and further strengthens our pharmacogenetic positioning strategy in emergency care more broadly."
As of 0900 BST, Genedrive shares were up 3.21% at 3.28p.
Reporting by Iain Gilbert at Sharecast.com